1 / 6

Erlocip 150mg - Anticancer drugs | view uses, side effects and price | MHP

Erlocip tablet has active ingredient Erlotinib, used to treat non-small cell lung cancer, pancreatic cancer and other various types of cancer. Erlocip is pharmacologically categorized as a tyrosine kinase inhibitor, acts on epidermal growth factor receptor. @MHP

RobbieRoyce
Download Presentation

Erlocip 150mg - Anticancer drugs | view uses, side effects and price | MHP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MILLION HEALTH PHARMACEUTICALS We will not dispense any prescription medication without a valid prescription from a licensed physician.

  2. ERLOTINIB Erlocip 150mg Tablets

  3. DESCRIPTION • INDICATION AND USAGE • Erlocip is primarily indicated for; Non small cell lung cancer: Erlocip is considered as second, maintenance or greater line treatment in NSCLC. It is used after failure of some chemotherapy regimens. Erlocip is involved in the treatment of non-small cell lung cancer patients whose cancer cells containing epidermal growth factor receptors on their surface. Erlocip is not used in combination with platinum based compounds. In pancreatic carcinoma: In metastatic stage, Erlocip is used in combination with gemcitabine. In this condition Erlocip is involved as first line treatment. Erlocip tablet has active ingredient Erlotinib, used to treat non-small cell lung cancer, pancreatic cancer and other various types of cancer. Erlocip is pharmacologically categorized as tyrosine kinase inhibitor, acts on epidermal growth factor receptor.

  4. DOSAGEMANAGEMENT • In renal impairment: Discontinue the Erlocip therapy permanently In gastrointestinal perforation and severe diarrhea: Stop the therapy In severe Bullous and exfoliative skin disorders: Discontinue the therapy and provide supportive measures In corneal perforation, therapy should be discontinuing permanently. Avoid concomitant use of Erlocip with CYP3A4 strong inhibitors, CYP3A4 strong inducers, cigarette smoking, gastric regulators etc. In NSCLC: The recommended dosage is 150mg should be taken as a single dose by administering on an empty stomach. In pancreatic cancer: The usual dosage of Erlocip is 100mg should be taken as a single dose by administering on an empty stomach by combining with gemcitabine. Dose alteration: In pulmonary toxicity: Interstitial lung disease, pulmonary failure: Discontinue the Erlocip therapy In severe hepatic failure: Stop the therapy permanently

  5. PREGNANCY & LACTATION • STORAGE • Erlocip should be stored at 25°C (77°F). Erlocip tablets should be keeping away from heat, light & moisture. The pregnancy category of Erlotinib is D Erlocip tablets are not recommended for pregnancy conditions, because it may cause fetal harm even to death. Breast feeding should not be recommended. • MISSED DOSE • Erlocip is a chemo medicine, prescribed by medical oncologist. If patients fail to take the dose of Erlocip tablet, consult with physician and follow the instructions. On the other hand, the missed dose should be skipped and follow the regular dosing schedule.

  6. CALL CONTACT US • +91-9940472902 MAIL VISIT US • millionhealthpharmaceuticals@gmail.com • https://millionpharma.com/ ADDRESS Portion 'A' First Floor, Old No. 131, New No. 50, Pedariyar Kovil Street, Seven Wells, Chennai - 600001. Tamilnadu, India

More Related